18F 3 fluoro 2 hydroxypropionate - Catholic University of Louvain/Telix Pharmaceuticals
Alternative Names: [18F]-FLacLatest Information Update: 17 Sep 2021
At a glance
- Originator Catholic University of Louvain
- Developer Telix Pharmaceuticals
- Class Antiacnes; Cardiotonics; Diagnostic agents; Halogenated hydrocarbons; Imaging agents; Keto acids; Pyruvates; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Sep 2021 18F 3 fluoro 2 hydroxypropionate licensed to Telix Pharmaceuticals for the diagnosis of Solid tumours
- 09 Sep 2021 Preclinical trials in Solid tumours (Diagnosis) in Australia (IV)
- 08 Sep 2017 Catholic-University-of-Louvain files for patent protection for 18F 3 fluoro 2 hydroxypropionate in France